ZA200604553B - Intranasal compositions - Google Patents

Intranasal compositions

Info

Publication number
ZA200604553B
ZA200604553B ZA200604553A ZA200604553A ZA200604553B ZA 200604553 B ZA200604553 B ZA 200604553B ZA 200604553 A ZA200604553 A ZA 200604553A ZA 200604553 A ZA200604553 A ZA 200604553A ZA 200604553 B ZA200604553 B ZA 200604553B
Authority
ZA
South Africa
Prior art keywords
compositions
salt
intranasal compositions
derivative
chitosan
Prior art date
Application number
ZA200604553A
Other languages
English (en)
Inventor
Smith Alan
Castile Jonathan
Watts Peter James
Original Assignee
Archimedes Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd
Publication of ZA200604553B publication Critical patent/ZA200604553B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200604553A 2003-12-05 2006-06-02 Intranasal compositions ZA200604553B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0328186.2A GB0328186D0 (en) 2003-12-05 2003-12-05 Intranasal compositions

Publications (1)

Publication Number Publication Date
ZA200604553B true ZA200604553B (en) 2009-09-30

Family

ID=29764615

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200604553A ZA200604553B (en) 2003-12-05 2006-06-02 Intranasal compositions

Country Status (26)

Country Link
US (1) US7947257B2 (xx)
EP (1) EP1696911B1 (xx)
JP (1) JP5103018B2 (xx)
KR (1) KR101194593B1 (xx)
CN (2) CN1901905A (xx)
AT (1) ATE460932T1 (xx)
AU (1) AU2004296586B2 (xx)
BR (1) BRPI0417350A2 (xx)
CA (1) CA2548559C (xx)
CY (1) CY1110664T1 (xx)
DE (1) DE602004026107D1 (xx)
DK (1) DK1696911T3 (xx)
ES (1) ES2357607T3 (xx)
GB (1) GB0328186D0 (xx)
HR (1) HRP20100343T1 (xx)
IL (1) IL176132A (xx)
ME (1) ME01070B (xx)
MX (1) MXPA06006239A (xx)
NO (1) NO335348B1 (xx)
NZ (1) NZ547848A (xx)
PL (1) PL1696911T3 (xx)
PT (1) PT1696911E (xx)
RS (1) RS51251B (xx)
SI (1) SI1696911T1 (xx)
WO (1) WO2005056008A1 (xx)
ZA (1) ZA200604553B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
EP1607117A4 (en) 2003-03-27 2007-10-24 Bioactis Ltd APPLICATOR FOR POWDER MEDICATION IN THE NOSE CAVE
EP1785145A4 (en) 2004-08-10 2008-08-13 Translational Res Ltd TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY
US7868016B2 (en) * 2005-07-13 2011-01-11 Baxter International Inc. Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
DE112005003703T5 (de) * 2005-09-23 2008-07-10 Amphenol Phoenix Co., Ltd., Hwaseong Öffnungs- und Schließvorrichtung in Gleitbauweise zur Verwendung in Mobiltelefonen
ATE544444T1 (de) * 2005-10-11 2012-02-15 Yissum Res Dev Co Zusammensetzungen für die nasale abgabe
JP5415769B2 (ja) 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
KR101368587B1 (ko) 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
JP6081102B2 (ja) * 2012-08-10 2017-02-15 テルモ株式会社 安定なグラニセトロン含有水性製剤
US10335398B2 (en) 2015-04-08 2019-07-02 Maxinase Life Sciences Limited Bioadhesive compositions for intranasal administration of granisetron
JP6905994B2 (ja) * 2016-01-12 2021-07-21 ノーティック ホールディングス インコーポレイテッド ベタメタゾン経口スプレー製剤及び運動失調の治療への使用方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2004270A1 (en) 1988-12-29 1990-06-29 William R. Michael Perfume microcapsules for use in granular detergent compositions
CA2042529C (en) 1990-08-10 2002-07-30 Chokyun Rha Polysaccharide article and uses therefor
US5929059A (en) * 1991-01-19 1999-07-27 Smithkline Beecham P.L.C. Pharmaceutical compositions containing granisetron and dexamethasone
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
GB9406171D0 (en) * 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
HRP950149A2 (en) 1994-04-13 1997-06-30 Janssen Pharmaceutica Nv Intranasal antimigrene composition
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
US20020132803A1 (en) * 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
JP2002255795A (ja) * 2001-02-26 2002-09-11 Teijin Ltd 経鼻投与用組成物
US20030044356A1 (en) * 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
CN1289085C (zh) * 2002-04-26 2006-12-13 中国人民解放军军事医学科学院毒物药物研究所 鼻腔喷雾剂
CN1332664C (zh) * 2002-04-26 2007-08-22 中国人民解放军军事医学科学院毒物药物研究所 鼻粉剂
GB0329918D0 (en) 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions

Also Published As

Publication number Publication date
JP5103018B2 (ja) 2012-12-19
NZ547848A (en) 2009-04-30
US7947257B2 (en) 2011-05-24
US20050142073A1 (en) 2005-06-30
JP2007513129A (ja) 2007-05-24
CN102389422A (zh) 2012-03-28
DK1696911T3 (da) 2010-06-28
NO335348B1 (no) 2014-11-24
CA2548559A1 (en) 2005-06-23
PT1696911E (pt) 2010-04-29
ME01070B (me) 2012-10-20
HRP20100343T1 (hr) 2010-11-30
CA2548559C (en) 2013-09-03
CN1901905A (zh) 2007-01-24
DE602004026107D1 (de) 2010-04-29
EP1696911B1 (en) 2010-03-17
AU2004296586B2 (en) 2010-08-12
PL1696911T3 (pl) 2010-08-31
BRPI0417350A2 (pt) 2009-03-10
KR20060126532A (ko) 2006-12-07
AU2004296586A1 (en) 2005-06-23
MXPA06006239A (es) 2006-08-23
KR101194593B1 (ko) 2012-10-25
IL176132A (en) 2010-12-30
WO2005056008A1 (en) 2005-06-23
ATE460932T1 (de) 2010-04-15
NO20062548L (no) 2006-08-15
SI1696911T1 (sl) 2010-06-30
CY1110664T1 (el) 2015-06-10
AU2004296586A2 (en) 2005-06-23
EP1696911A1 (en) 2006-09-06
ES2357607T3 (es) 2011-04-28
GB0328186D0 (en) 2004-01-07
IL176132A0 (en) 2006-10-05
RS51251B (sr) 2010-12-31

Similar Documents

Publication Publication Date Title
IL176132A0 (en) Intranasal compositions
UA90518C2 (ru) Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
MX2020008616A (es) Rocio de fentanilo sublingual.
MXPA06000675A (es) Derivado de quinolona o sal del mismo.
IL170690A0 (en) Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2009017837A3 (en) Sublingual fentanyl spray
WO2004021968A3 (en) Solution for ungual application
HK1080447A1 (en) Retinol derivatives, their use in the treatment ofcancer and for potentiating the efficacy of other cytotoxic agents
UA84712C2 (xx) N-заміщені піразоліламідилбензімідазоліли як c-kit інгібітори$n-замещенные пиразолиламидилбензимидазолилы как c-kit ингибиторы
EP1770085A4 (en) DIAMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND FUNGICIDE CONTAINING THE DERIVATIVE AS ACTIVE INGREDIENT
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
AU2002228317A1 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2001032181A3 (en) Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
AU2003245812A1 (en) Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
AU2003201745A1 (en) Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
IT1302682B1 (it) Composizioni farmaceutiche orali contenenti buprenorfina
TW200733963A (en) Cough inhibitor
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
WO2004087045A3 (en) Devices, methods, and compositions to prevent restenosis
EP1362590A8 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
MXPA04003851A (es) Antipruriticos.
HK1061647A1 (en) Pharmaceutical compositions of rapmycins
TW200510335A (en) Water-soluble phenylpyridazine derivatives and medicines containing the same